Melanocyte-stimulating hormone release inhibiting factor
Cat. No. 1929
Alternative Names: Pro-Leu-Gly amide, MIF-I, PLG
Biological ActivityInhibitor of melanocyte-stimulating hormone (MSH) release. Blocks the release of α-MSH, increases brain dopamine levels and antagonizes physiological and behavioral opioid effects in vivo.
(Modifications: Gly-3 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Kavaliers and Hirst (1986) Inhibitory influences of FMRFamide and PLG on stress-induced opioid analgesia and activity. Brain Res. 372 370. PMID: 2871903.
Mishra et al (1983) Pharmacology of L-Prolyl-L-Leucyl-Glycinamide (PLG): a review. Methods Find.Exp.Clin.Pharmacol. 5 203. PMID: 6136640.
Pugsley and Lippmann (1977) Synthetic melanocyte stimulating hormone release inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover. Arzneimittelforschung 27 2293. PMID: 23796.
Plotnikoff and Kastin (1974) Pharmacological studies with a tripeptide, Prolyl-Leucyl Glycine amide. Arch.Int.Pharmacodyn.Ther. 211 211. PMID: 4156639.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Melanocyte-stimulating hormone release inhibiting factor from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Melanocyte-stimulating hormone release inhibiting factor, supplier, α-MSH, alpha-MSH, a-MSH, release, inhibits, inhibitors, melanocortin, receptors, Tocris Bioscience, Melanocortin (MC) Receptor products
Find multiple products by catalog number
New Products in this Area
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.